

Special Issue

Emerging Therapeutic Approaches for Gastrointestinal Malignancies and the Tumour Microenvironment

Message from the Guest Editors

In this Special Issue, a collection of studies on the current state of preclinical and clinical investigations shall be assembled. Studies that investigate new promising therapeutic targets, and innovative pathways as well as submissions that evaluate targeted therapies in combination with immuno-therapy and/or conventional systemic therapies, are encouraged. The aim is to summarize the interdisciplinary nature of gastrointestinal treatment, with a focus on targeted therapeutic strategies. Potential topics include, but are not limited to, the following:

- Current and new therapeutic targets in gastrointestinal cancer subtypes;
- Diagnosis and selection of patients with gastrointestinal cancers for targeted therapy;
- Personalized medicine initiatives for gastrointestinal malignancies;
- Role of multi-modality treatment in the setting of neoadjuvant therapy;
- Implications of the combination of targeted therapeutics with immune-therapies and/or conventional chemotherapies.

Guest Editors

Dr. Khurum Khan

Dr. Kai-Keen Shiu

Umair Mahmood

Deadline for manuscript submissions

closed (15 December 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/180540

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)